

Assessment of genetically modified maize MON 87460 for renewal authorisation under Regulation (EC) No 1829/2003 (dossier GMFF-2023-21251)

EFSA Panel on Genetically Modified Organisms (GMO) | Josep Casacuberta | Francisco Barro | Albert Braeuning | Ruud de Maagd | Michelle M. Epstein | Thomas Frenzel | Jean-Luc Gallois | Frits Koning | Antoine Messéan | F. Javier Moreno | Fabien Nogué | Giovanni Savoini | Alan H. Schulman | Christoph Tebbe | Eve Veromann | Ana M. Camargo | Tilemachos Goumperis | Paolo Lenzi | Pietro Piffanelli | Tommaso Raffaello | Elena Sánchez-Brunete

Correspondence: [Ask a Question](#)

The declarations of interest of all scientific experts active in EFSA's work are available at <https://open.efsa.europa.eu/experts>.

Abstract

Following the submission of dossier GMFF-2023-21251 under Regulation (EC) No 1829/2003 from Bayer CropScience LP, the Panel on Genetically Modified Organisms of the European Food Safety Authority was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the drought tolerant genetically modified maize MON 87460, for food and feed uses, excluding cultivation within the European Union. The data received in the context of this renewal application contained post-market environmental monitoring reports, an evaluation of the literature retrieved by a scoping review, a search for additional studies performed by or on behalf of the applicant and updated bioinformatics analyses. The GMO Panel assessed these data for possible new hazards, modified exposure or new scientific uncertainties identified during the authorisation period and not previously assessed in the context of the original application. Under the assumption that the DNA sequence of the event in maize MON 87460 considered for renewal is identical to the sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in renewal dossier GMFF-2023-21251 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize MON 87460.

KEYWORDS

Articles 11 and 23, maize, MON 87460, Regulation (EC) No 1829/2003, renewal

This is an open access article under the terms of the [Creative Commons Attribution-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

© 2025 European Food Safety Authority. *EFSA Journal* published by Wiley-VCH GmbH on behalf of European Food Safety Authority.

CONTENTS

Abstract.....	1
Summary	3
1. Introduction	4
1.1. Background	4
1.2. Terms of Reference as provided by the requestor	4
2. Data and Methodologies	4
2.1. Data	4
2.1.1. Post-market monitoring and post-market environmental monitoring reports	5
2.1.2. Systematic search and evaluation of literature	5
2.1.3. Updated bioinformatics	5
2.1.4. Additional documents or studies performed by or on behalf of the applicant	6
2.1.5. Overall assessment	6
2.1.6. Monitoring plan and proposal for improving the conditions of the original authorisation	6
2.2. Methodologies.....	6
3. Assessment	6
3.1. Evaluation of the post-market monitoring and post-market environmental monitoring reports	6
3.2. Evaluation of the systematic search and evaluation of literature	6
3.3. Evaluation of the updated bioinformatics analyses.....	6
3.4. Evaluation of the additional documents or studies performed by or on behalf of the applicant	7
3.5. Presence of the antimicrobial resistance (AMR) gene NPTII in maize MON 8746019	7
3.6. Evaluation of the overall assessment.....	7
3.7. Evaluation of the monitoring plan and proposal for improving the conditions of the original authorisation	7
4. Conclusions.....	8
5. Documentation as provided to EFSA	8
Abbreviations	8
Acknowledgements	8
Requestor	8
Question number	8
Copyright for non-EFSA content.....	8
Panel members	8
References.....	8
Appendix A.....	10

SUMMARY

Following the submission of dossier GMFF-2023-21251 under Regulation (EC) No 1829/2003 from Bayer CropScience LP, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the drought tolerant genetically modified maize MON 87460. The scope of the renewal dossier GMFF-2023-21251 is for the renewal of the placing on the market of maize MON 87460 for food and feed uses, excluding cultivation within the European Union (EU).

In delivering its scientific opinion, the GMO Panel took into account dossier GMFF-2023-21251, additional information provided by the applicant, scientific comments submitted by the EU Member States and relevant scientific publications. The data received in the context of the renewal dossier GMFF-2023-21251 contained: post-market environmental monitoring reports, an evaluation of the literature retrieved by a scoping review, a search for additional studies performed by or on behalf of the applicant and updated bioinformatics analyses. The GMO Panel assessed these data for possible new hazards, modified exposure or new scientific uncertainties identified during the authorisation period and not previously assessed in the context of the original application.

Under the assumption that the DNA sequence of the event in maize MON 87460 considered for renewal is identical to the sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in renewal dossier GMFF-2023-21251 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize MON 87460 (EFSA GMO Panel, [2012](#)).

1 | INTRODUCTION

1.1 | Background

On 12 March 2024, the European Food Safety Authority (EFSA) received from the European Commission (EC) dossier GMFF-2023-21251 for the renewal of the authorisation of maize MON 87460 (Unique Identifier MON-8746Ø-4), submitted by Bayer CropScience LP (hereafter referred to as 'the applicant') according to Regulation (EC) No 1829/2003.¹

Following receipt of dossier GMFF-2023-21251, EFSA informed the Member States (MS) and made the summary of the application available to the public on the Open EFSA portal.²

EFSA checked the dossier for compliance with the relevant requirements of Regulation (EC) No 1829/2003 and Regulation (EU) No 503/2013³ and, when needed, asked the applicant to supplement the initial application. On 5 July 2024, EFSA declared the application valid and made the valid application available to the MS and the European Commission (EC).

Following the submission of application EFSA-GMO-NL-2009-70 and the publication of the EFSA scientific opinion (EFSA GMO Panel, 2012), the placing on the market of maize MON 87460 was authorised by Commission Implementing Decision (EU) 2015/683 for (a) foods and food ingredients containing, consisting of, or produced from MON 8746Ø-4 maize, (b) feed containing, consisting of, or produced from MON 8746Ø-4 maize, (c) MON 8746Ø-4 maize in products containing it or consisting of it for any other use than (a) and (b), with the exception of cultivation.⁴ A copy of this authorisation was provided by the applicant.⁵

From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter referred to as 'the GMO Panel') endeavoured to respect a time limit of 6 months to issue a scientific opinion on dossier GMFF-2023-21251. This time limit was extended whenever EFSA and/or its GMO Panel requested supplementary information to the applicant. According to Regulation (EC) No 1829/2003, any supplementary information provided by the applicant during the risk assessment was made available to the MS and EC (for further details, see the Section 5).

In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment bodies of the MS, including national Competent Authorities within the meaning of Directive 2001/18/EC.⁶ The MS had 3 months to make their opinion known on dossier GMFF-2023-21251 as of date of validity.

1.2 | Terms of Reference as provided by the requestor

EFSA and its GMO Panel were requested to carry out a scientific risk assessment of maize MON 87460 for the renewal of authorisation, according to Articles 11 and 23 of Regulation (EC) No 1829/2003.

According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report requested under Articles 6(6) and 18(6) of that Regulation including the opinions of the nominated risk assessment bodies of the MS.⁷

In addition to the present scientific opinion on maize MON 87460, EFSA and its GMO Panel were also asked to report on the particulars listed under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003. The relevant information is made available in the OpenEFSA portal,⁸ including the information required under Annex II to the Cartagena Protocol, a labelling proposal, a post-market environmental monitoring (PMEM) plan as provided by the applicant; the method(s), validated by the Community reference laboratory, for detection, including sampling, identification of the transformation event in the food-feed and/or foods-feeds produced from it and the appropriate reference materials.

2 | DATA AND METHODOLOGIES

2.1 | Data

The applicant has submitted a confidential and a non-confidential version of the dossier GMFF-2023-21251 following the EFSA requirements as detailed in EFSA GMO Panel (2015) and EFSA (2021).

¹Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed. OJ L 268, 18.10.2003, p. 1–23.

²Available online: <https://open.efsa.europa.eu/questions/EFSA-Q-2024-00165?search=EFSA-Q-2024-00165>.

³Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.

⁴Commission Implementing Decision (EU) 2015/683 of 24 April 2015 authorising the placing on the market of products containing, consisting of, or produced from genetically modified maize MON 87460 (MON 8746Ø-4) pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council.

⁵Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – The authorization for the placing of the GM food and/or feed onto the market in EU.

⁶Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.

⁷Opinions of the nominated risk assessment bodies of EU Member States can be found at the Open EFSA Portal <https://open.efsa.europa.eu/questions>, querying the assigned Question Number.

⁸<https://open.efsa.europa.eu/questions/EFSA-Q-2024-00165?search=EFSA-Q-2024-00165>.

In accordance with Art. 38 of the Regulation (EC) No 178/2002 and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, the non-confidential version of the dossier has been published on OpenEFSA.⁹ According to Art. 32c(2) of Regulation (EC) No 178/2002¹⁰ and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre-submission phase and public consultations,¹¹ EFSA carried out a public consultation on the non-confidential version of the dossier from 25 July to 15 August 2025 for which no comments were received.

The GMO Panel based its scientific assessment of maize MON 87460 on the valid dossier GMFF-2023-21251, additional information provided by the applicant during the risk assessment, relevant scientific comments submitted by EU MS, and peer-reviewed scientific publications.

In the frame of the contracts OC/EFSA/MESE/2022/03-01-SC17 and OC/EFSA/GMO/2021/06, the contractor performed preparatory work and delivered reports on the methods applied by the applicant in performing literature search and updated bioinformatic analyses.

2.1.1 | Post-market monitoring and post-market environmental monitoring reports¹²

Based on the outcome of the initial food and feed risk assessment, a post-market monitoring plan for monitoring of GM food and feed was not required by the authorisation decision. The implementation of a PMEM plan, consisting of a general surveillance plan to check for any adverse effects on the environment arising from maize MON 87460, was a condition for the authorisation. As no potential adverse environmental effects were identified in the environmental risk assessment of maize MON 87460 (EFSA GMO Panel, 2012), case-specific monitoring was not considered necessary by the GMO Panel.

The applicant provided 10 annual PMEM reports covering a reporting period from April 2015 to June 2024. The annual PMEM plans submitted by the applicant included (1) commodity crop (GM and non GM) imports into the EU by country of origin and destination; (2) the description of a centralised system established by EuropaBio¹³ for the collection of information recorded by various operators (federations involved in maize import and processing) on any observed adverse effect(s) on human health and the environment arising from handling of maize possibly containing maize MON 87460; (3) the reports of the surveillance activities conducted by such operators; and (4) the review of relevant scientific peer-reviewed studies retrieved from literature searches.

2.1.2 | Systematic search and evaluation of literature¹⁴

In addition to the separate searches provided as part of the annual PMEM reports, the applicant performed scoping reviews covering the period from January 2014 to September 2024, in accordance with the recommendations on literature search outlined in EFSA (2010, 2019).

Searches in electronic bibliographic databases and in websites of relevant organisations were performed to identify relevant publications. After applying the eligibility/inclusion criteria defined a priori by the applicant, 10 publications were identified as relevant for food and feed safety assessment. The relevant publications are listed in Appendix A.

2.1.3 | Updated bioinformatics¹⁵

At the time of submission of the renewal dossier, the applicant provided a complete bioinformatics dataset for maize MON 87460 including an analysis of the insert and flanking sequences, an analysis of the potential similarity to allergens and toxins of the newly expressed proteins and of all possible open reading frames (ORFs) within the insert and spanning the junction sites, an analysis of possible horizontal gene transfer (EFSA, 2017), and a safety assessment of the newly expressed proteins CspB and NPTII regarding their capacity to trigger celiac disease symptoms (EFSA GMO Panel, 2017). The outcome of the updated bioinformatic analyses is presented in Section 3.3.

⁹<https://open.efsa.europa.eu/questions/EFSA-Q-2024-00165?search=EFSA-Q-2024-00165>.

¹⁰Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, p. 1–48.

¹¹Decision available at: https://www.efsa.europa.eu/sites/default/files/corporate_publications/files/210111-PAs-pre-submission-phase-and-public-consultations.pdf.

¹²Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – Post-market monitoring and post-market environmental monitoring reports; additional information: 26/8/2025.

¹³The responsibilities of EuropaBio in coordinating activities of technology providers on the post-market environmental monitoring of GM crops were taken over by CropLife Europe as of 1st January 2021.

¹⁴Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – New information-Systematic search and evaluation of the literature; additional information: 2/12/2024, 23/6/2025.

¹⁵Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – New information- Updated bioinformatics; additional information: 2/12/2025, 23/6/2025, 26/8/2025, 24/10/2025; spontaneous information: 23/06/2025.

2.1.4 | Additional documents or studies performed by or on behalf of the applicant¹⁶

In line with the renewal guidance requirements (EFSA, 2021; EFSA GMO Panel, 2015), the applicant provided an overview on the worldwide approvals of maize MON 87460 and searched for any available full reports of studies performed by or on behalf of the applicant over the course of the authorisation period and not previously submitted to the EU.

The relevance of the listed studies for molecular characterisation, human and animal safety and the environment was assessed by the applicant.

2.1.5 | Overall assessment¹⁷

The applicant provided an overall assessment concluding that information provided in the application for renewal of authorisation of maize MON 87460 for food and feed uses in the EU does not change the outcome of the original EFSA risk assessment (EFSA GMO Panel, 2012).

2.1.6 | Monitoring plan and proposal for improving the conditions of the original authorisation¹⁸

The applicant indicated in the dossier that the environmental post-market monitoring plan is appropriate and does not need any changes.

2.2 | Methodologies

The GMO Panel assessed the application for renewal of the authorisation of maize MON 87460 for food and feed uses in accordance with Articles 11 and 23 of Regulation (EC) No 1829/2003. The GMO Panel took into account the requirements described in its guideline for the risk assessment of renewal applications of GM food and feed authorised under Regulation (EC) No 1829/2003 (EFSA GMO Panel, 2015). The opinions raised by the nominated risk assessment bodies of EU Member States were taken into consideration during the scientific risk assessment.

3 | ASSESSMENT

3.1 | Evaluation of the post-market monitoring and post-market environmental monitoring reports

The GMO Panel assessed the 10 PMEM reports submitted by the applicant. During the general surveillance activities covering the authorisation period of maize MON 87460, no adverse effects were reported by the applicant. This was confirmed by the evaluation of the results of the annual literature searches and the annual communications by the operators collating reports of adverse effects from their member organisations and companies. No safety concerns were identified by the GMO Panel.

3.2 | Evaluation of the systematic search and evaluation of literature

The GMO Panel assessed the applicant's literature searches on maize MON 87460 and the newly expressed proteins CspB and NPTII. The quality of the performed literature searches is acceptable.

The GMO Panel reviewed the publications identified as relevant by the applicant. No new information raising safety concerns for human and animal health and the environment which would change the original risk assessment conclusions on maize MON 87460 was identified (EFSA GMO Panel, 2012).

3.3 | Evaluation of the updated bioinformatics analyses

Updated bioinformatics analyses to assess the potential interruption of maize endogenous genes confirm previous results indicating that no known endogenous genes were interrupted (EFSA GMO Panel, 2012, 2019, 2021).

¹⁶Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – New information-Additional documents or studies performed by or on behalf of the applicant; additional information: 23/6/2025.

¹⁷Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – New information- Overall assessment; additional information: 23/6/2025.

¹⁸Dossier number: GMFF-2023-21251. Technical dossier – Information to support the risk assessment – Post-market environmental monitoring plan.

The updated analyses of the amino acid sequence of the newly expressed proteins CspB and NPTII reveal no significant similarities to toxins, allergens or immunogenic gluten-related epitopes. Moreover, the updated bioinformatics analyses of the newly created ORFs within the insert and spanning the junctions between the insert and genomic DNA confirm previous results indicating that the production of new peptides showing significant similarities to toxins or allergens is highly unlikely (EFSA GMO Panel, 2012, 2019, 2021).

The updated bioinformatics analyses for possible horizontal gene transfer for event MON 87460 confirm previous conclusions (EFSA GMO Panel, 2012, 2019, 2021). Given the results of this analysis and that a transfer of the recombinant DNA of maize MON 87460 to environmental bacteria will only have a negligible effect on the natural background of environmental antibiotic resistances, the GMO Panel identified no safety concern linked to an unlikely but theoretically possible HGT.

3.4 | Evaluation of the additional documents or studies performed by or on behalf of the applicant

Taking into account (i) the relevance for molecular characterisation, human and animal safety and the environment; and (ii) the scope of this renewal application, the applicant declared that there were no unpublished studies produced, controlled or sponsored by the applicant or provided to the applicant by a third party and not previously submitted to the EU since maize MON 87460 was authorised.

3.5 | Presence of the antimicrobial resistance (AMR) gene NPTII in maize MON 87460¹⁹

Maize MON 87460 contains the *nptII* gene, which is expressed in the plant, conferring resistance to kanamycin and neomycin. The GMO Panel collected information from the applicant, the European Medical Agency (EMA) and European Centre for Disease Prevention and Control (ECDC) regarding any reported differences in the usage of kanamycin and neomycin for humans and animals, any changes in the used volumes of kanamycin and neomycin for humans and animals, and whether the *nptII* gene confers resistance to antibiotics newly introduced in the market in the EU from the time of authorisation, other than those mentioned above.

In summary, the information provided did not identify changes in the usage of these antibiotics for humans and animals, such as new or suspended/withdrawn uses or uses in emergency situations. Based on the available data, an overall decrease in the use of these antibiotics for humans and animals in the EU from 2014 was observed. The applicant did not report any new antibiotic introduced into the EU market to which *nptII* confers resistance since 2014. In addition, as described in Section 3.3, the updated bioinformatic analyses for possible horizontal gene transfer (HGT) for the event MON 87460 confirmed previous conclusions (EFSA GMO Panel, 2012).

Taken together, this information did not provide any new evidence that would change the conclusions of the original risk assessment related to the presence of the AMR gene *nptII* in maize MON 87460.

3.6 | Evaluation of the overall assessment

The GMO Panel evaluated the overall assessment provided by the applicant and confirms that there is no evidence in renewal dossier GMFF-2023-21251 indicating new hazards, relevant changes in exposure or scientific uncertainties that would change previous conclusions on maize MON 87460.

3.7 | Evaluation of the monitoring plan and proposal for improving the conditions of the original authorisation

The PMEM plan covers general surveillance of imported GM plant material, including maize MON 87460. This general surveillance is coordinated by CropLife Europe and implemented by selected operators (federations involved in maize grains import and processing). In addition, the applicant reviews relevant scientific publications retrieved from literature searches on an annual basis. The GMO Panel is of the opinion that the scope of the plan provided by the applicant is consistent with the scope of dossier GMFF-2023-21251 but reminds that the final adoption and implementation of the PMEM plan falls outside the mandate of EFSA.

¹⁹Dossier number: GMFF-2023-21251. Technical dossier – New Information - Overall assessment; additional information: 23/6/2025.

4 | CONCLUSIONS

Under the assumption that the DNA sequence of the event in maize MON 87460 considered for renewal is identical to the sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in renewal dossier GMFF-2023-21251 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on maize MON 87460 (EFSA GMO Panel, 2012).

5 | DOCUMENTATION AS PROVIDED TO EFSA

- Letter from the European Commission to EFSA received on 12 March 2024 for the continued marketing of genetically modified maize MON 87460 submitted in accordance with articles 11 and 23 of Regulation (EC) No 1829/2003 by Bayer CropScience LP (GMFF-2023-21251).
- The application was made valid on 5 July 2024.
- Additional Information (Clock 1) was requested on 7 October 2024.
- Additional Information (Clock 1) was received on 2 December 2024.
- Additional Information (Clock 2) was requested on 18 December 2024.
- Additional Information (Clock 2) was received on 23 June 2025.
- Additional Information (Clock 3) was requested on 1 August 2025.
- Additional Information (Clock 3) was received on 26 August 2025.
- Additional Information (Clock 4) was requested on 8 August 2025.
- Additional Information (Clock 4) was received on 26 August 2025.
- Additional Information (Clock 5) was requested on 22 October 2025.
- Additional Information (Clock 5) was received on 24 October 2025.

ABBREVIATIONS

GM	genetically modified
GMO	Panel EFSA Panel on Genetically Modified Organisms
HGT	horizontal gene transfer
ORFs	open reading frames
PMEM	post-market environmental monitoring

ACKNOWLEDGEMENTS

The Panel wishes to thank the members of its standing Working Groups on Molecular Characterization, Food/Feed and Environmental Risk Assessment for the preparatory work on this scientific opinion.

REQUESTOR

European Commission

QUESTION NUMBER

EFSA-Q-2024-00165

COPYRIGHT FOR NON-EFSA CONTENT

EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source.

PANEL MEMBERS

Josep Casacuberta, Francisco Barro, Albert Braeuning, Ruud de Maagd, Michelle M. Epstein, Thomas Frenzel, Jean-Luc Gallois, Frits Koning, Antoine Messéan, F. Javier Moreno, Fabien Nogué, Giovanni Savoini, Alan H. Schulman, Christoph Tebbe, and Eve Veromann.

REFERENCES

- EFSA (European Food Safety Authority). (2010). Application of systematic review methodology to food and feed safety assessments to support decision making. *EFSA Journal*, 8(6), 1637. <https://doi.org/10.2903/j.efsa.2010.1637>
- EFSA (European Food Safety Authority), Gennaro, A., Gomes, A., Herman, L., Nogué, F., Papadopoulou, N., & Tebbe, C. (2017). Technical report on the explanatory note on DNA sequence similarity searches in the context of the assessment of horizontal gene transfer from plants to microorganisms. *EFSA Supporting Publications*, 14(7), EN-1273. <https://doi.org/10.2903/sp.efsa.2017.EN-1273>
- EFSA (European Food Safety Authority), Devos, Y., Guajardo, I. M., Álvarez, F., & Glanville, J. (2019). Explanatory note on literature searching conducted in the context of GMO applications for (renewed) market authorisation and annual post-market environmental monitoring reports on GMOs authorised in the EU market - note on literature searching to GMO risk assessment guidance. *EFSA Journal*, 16(4), EN-1614. <https://doi.org/10.2903/sp.efsa.2019.EN-1614>
- EFSA (European Food Safety Authority). (2021). Administrative guidance for the preparation of renewal applications on genetically modified food and feed. *EFSA Supporting Publications*, 18(3), EN-6474. <https://doi.org/10.2903/sp.efsa.2021.EN-6474>

- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms). (2012). Scientific Opinion on an application (reference EFSA-GMO-NL-2009-70) for the placing on the market of genetically modified drought tolerant maize MON 87460 for food and feed uses, import and processing under regulation (EC) No 1829/2003 from Monsanto. *EFSA Journal*, 10(11), 2936. <https://doi.org/10.2903/j.efsa.2012.2936>
- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms). (2015). Guidance for renewal applications of genetically modified food and feed authorised under regulation (EC) No 1829/2003. *EFSA Journal*, 13(6), 4129. <https://doi.org/10.2903/j.efsa.2015.4129>
- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), Naegeli, H., Birch, A. N., Casacuberta, J., De Schrijver, A., Gralak, M. A., Guerche, P., Jones, H., Manachini, B., Messean, A., Nielsen, E. E., Nogué, F., Robaglia, C., Rostoks, N., Sweet, J., Tebbe, C., Visioli, F., Wal, J.-M., Eigenmann, P., ... Fernandez Dumont, A. (2017). Guidance on allergenicity assessment of genetically modified plants. *EFSA Journal*, 15(5), 4862. <https://doi.org/10.2903/j.efsa.2017.4862>
- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), Naegeli, H., Bresson, J.-L., Dalmay, T., Dewhurst, I. C., Epstein, M. M., Firbank, L. G., Guerche, P., Hejatko, J., Moreno, F. J., Mullins, E., Nogué, F., Rostoks, N., Sánchez Serrano, J. J., Savoini, G., Veromann, E., Veronesi, F., Álvarez, F., Ardizzone, M., ... Paraskevopoulos, K. (2019). Scientific Opinion on the assessment of genetically modified maize MON87427 x MON 87460 x MON 89034 x MIR162 x NK603 and subcombinations, for food and feed uses, under regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2016-134). *EFSA Journal*, 17(8), 5774. <https://doi.org/10.2903/j.efsa.2019.5774>
- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), Naegeli, H., Bresson, J.-L., Dalmay, T., Dewhurst, I. C., Epstein, M. M., Firbank, L. G., Guerche, P., Hejatko, J., Moreno, F. J., Mullins, E., Nogué, F., Rostoks, N., Sánchez Serrano, J. J., Savoini, G., Veromann, E., Veronesi, F., Álvarez, F., Ardizzone, M., ... Raffaello, T. (2021). Scientific Opinion on the assessment of genetically modified maize MON 87427 x MON 87460 x MON 89034 x 1507 x MON 87411 x 59122 and subcombinations, for food and feed uses, under regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2017-139). *EFSA Journal*, 19(1), 6351. <https://doi.org/10.2903/j.efsa.2021.6351>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), Casacuberta, J., Barro, F., Braeuning, A., de Maagd, R., Epstein, M. M., Frenzel, T., Gallois, J.-L., Koning, F., Messéan, A., Moreno, F. J., Nogué, F., Savoini, G., Schulman, A. H., Tebbe, C., Veromann, E., Camargo, A. M., Goumperis, T., Lenzi, P., ... Sánchez-Brunete, E. (2025). Assessment of genetically modified maize MON 87460 for renewal authorisation under Regulation (EC) No 1829/2003 (dossier GMFF-2023-21251). *EFSA Journal*, 23(12), e9744. <https://doi.org/10.2903/j.efsa.2025.9744>

APPENDIX A

List of relevant publications identified by the applicant through literature searches (January 2014 to September 2024)

References

- CIFA (Canadian Food Inspection Agency). (2017). DD2010-82 Determination of the Safety of Monsanto Canada Inc.'s corn (*Zea mays* L.) event MON 87460. <https://inspection.canada.ca/plant-varieties/plants-with-novel-traits/approved-under-review/decision-documents/dd2010-82/eng/1331755614111/1331755683913>
- Chang, J., Clay, D. E., Hansen, S. A., Clay, S. A., and Schumacher, T. E. (2014). Water stress impacts on transgenic drought-tolerant corn in the Northern Great Plains. *Agronomy Journal*, *106*, 125–130.
- Fischer, J., Nemali, K., Raychaudhuri, A., Corbin, J., Shirrell, T., O'Connor, D., Barberis, L., Klug, K., Li, X., and Singh, D. (2020). Yield component responses of biotechnology-derived drought tolerant maize under controlled environment conditions. *Agricultural and Environmental Letters*, *5*, e20007.
- Mason, S., Galusha, T., and Kmail, Z. (2018). Planting date influence on yield of drought-tolerant maize with different maturity classifications. *Agronomy Journal*, *110*, 293–299.
- Mason, S., Kmail, Z., Galusha, T., and Jukić, Ž. (2019). Path analysis of drought tolerant maize hybrid yield and yield components across planting dates. *Journal of Central European Agriculture*, *20*, 194–207.
- National Technical Commission on Biosafety. (2016). CTNBio, 2016, Parecer Técnico no 5224: Liberação Comercial: MON 87460. <https://ctnbio.mctic.gov.br/documents/566529/2077859/Parecer+T%C3%A9cnico+n%C2%BA%205224-2016/dcbf1422-d21e-4220-8224-27c9fe501a7d?version=1.0>
- Nemali, K. S., Bonin, C., Dohleman, F. G., Stephens, M., Reeves, W. R., Nelson, D. E., Castiglioni, P., Whitsel, J. E., Sammons, B., and Silady, R. A. (2015). Physiological responses related to increased grain yield under drought in the first biotechnology-derived drought-tolerant maize. *Plant, Cell & Environment*, *38*, 1866–1880.
- Sammons, B., Whitsel, J., Stork, L. G., Reeves, W., and Horak, M. (2014). Characterization of drought-tolerant maize MON 87460 for use in environmental risk assessment. *Crop Science*, *54*, 719–729.
- Venkatesh, T. V., Cook, K., Liu, B., Perez, T., Willse, A., Tichich, R., Feng, P., Harrigan, G. G. (2015). Compositional differences between near-isogenic GM and conventional maize hybrids are associated with backcrossing practices in conventional breeding. *Plant Biotechnology Journal*, *13*, 200–210
- Wang, C., Burzio, L. A., Koch, M. S., Silvanovich, A., and Bell, E. (2015). Purification, characterization and safety assessment of the introduced cold shock protein B in DroughtGard™ maize. *Regulatory Toxicology and Pharmacology*, *71*, 164–173.